The p3 trial for 525 was proposed when Prana were in talks with large Pharma prior to the GFC biting, the financial meltdown cause Pharma to run away scared and Prana were left to go it alone.
This p2 trial is to "fill in the gaps" and bring Pharma back to the table. However with the demise of the other Pharma trials it becomes a real possibility that Prana may be in a position to go it alone. This is a difficult path and management may prefer a top deal from the likes of Pfizer or JNJ that will speed things up considerably.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.001(11.1%) |
Mkt cap ! $91.27M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.0¢ | 0.9¢ | $9.419K | 1.001M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 63876237 | 0.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.0¢ | 4097409 | 8 |
View Market Depth
| Last trade - 16.15pm 04/07/2025 (20 minute delay) ? |
| ATH (ASX) Chart |